Tyra Biosciences, Inc. TYRA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Tyra Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tyra Biosciences, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tyra Biosciences, Inc.'s additional paid-in capital?
- Tyra Biosciences, Inc. (TYRA) reported additional paid-in capital of $798.03M in Q1 2026.
- How has Tyra Biosciences, Inc.'s additional paid-in capital changed year-over-year?
- Tyra Biosciences, Inc.'s additional paid-in capital increased by 32.5% year-over-year, from $602.3M to $798.03M.
- What is the long-term trend for Tyra Biosciences, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Tyra Biosciences, Inc.'s additional paid-in capital has grown at a 327.9% compound annual growth rate (CAGR), from $439K to $630.04M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.